BCL7C

Across TCGA pan-cancer cohorts, BCL7C mass-spec protein is linked to patient survival in 8 of 34 cancer types, making it a survival-associated BCL7C data layer compared with 22 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher BCL7C mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated BCL7C expression acts as an unfavorable survival marker, although some lineages such as PDAC and COAD show a favorable association.

HNSC, PDAC, and COAD are the cancer types where BCL7C mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	IV	0.473	0.841	<.001	60	view →
PDAC	OS	Median	All	0.558	0.290	<.001	45	view →
COAD	DFS	Median	All	1.000	0.866	.027	36	view →
LUAD	OS	Tertile	All	0.930	0.727	.003	19	view →
UCEC	OS	Median	II,III,IV	0.638	1.000	.014	10	view →
CCRCC	OS	Median	IV	1.000	0.202	.034	8	view →
GBM	OS	Median	All	0.806	0.906	.031	2	view →
LSCC	OS	Median	II,III,IV	0.790	0.914	.040	1	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

BCL7C–HNSC (DFS)

Open the HNSC breakdown →